CrushSCI.com
104.4Average days
91Median days
19Fastest days
203Longest days
2272025 publications

Paper Review Records

All Paper Review Records

27 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

81 days

Impact of race/ethnicity, donor and recipient age, and donor on survival after allogeneic transplant in the post-transplant cyclophosphamide era

Authors
Megan M. Herr; Nisha M. Nair; Nandita Khera; Shernan G. Holtan; Theresa HahnShow moreShow less
Affiliations
1. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 2. Mayo Clinic, Phoenix, USAShow moreShow less
Source PDF DOI Publisher page
194 days

Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)

Authors
Douglas W. Sborov; Anuj K. Mahindra; Vera J. Suman; Elisabet Esteve Manasanch; Prashant Kapoor; Tibor Kovacsovics; Cesar Rodriguez; Benjamin Parsons; Jose Eugenio Najera; Lyle Goldman; Destin Carlisle; Yujia Wen; Shira H. Dinner; Ilene A. Galinsky; LeAnne Kennedy; James Omel; Philip McCarthy; Saad Usmani; Paul G. RichardsonShow moreShow less
Affiliations
1. University of Utah, Huntsman Cancer Institute, Salt Lake City, USA; 2. Scripps MD Anderson Cancer Center, La Jolla, USA; 3. Alliance Statistics Data and Management Center, Mayo Clinic, Rochester, USA; 4. University of Texas MD Anderson Cancer Center, Houston, USA; 5. Mayo Clinic, Rochester, USA; 6. City of Hope Cancer Center, Phoenix, USA; 7. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; 8. Gundersen Health, La Crosse, USA; 9. Cancer Centers of Southwest Oklahoma, Oklahoma, USA; 10. Ascension Health, Southfield, USA; 11. Alliance Protocol Operations Office, University of Chicago, Chicago, USA; 12. Dana-Farber/Partners Cancer Care, Boston, USA; 13. Wake Forest Baptist Health/Atrium Health Wake Forest Baptist, Winston-Salem, USA; 14. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 15. Memorial Sloan Kettering Cancer Center, New York, USA; 16. Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, USAShow moreShow less
Source PDF DOI Publisher page
85 days

Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma

Authors
Tamer Hellou; Daniel G. Packard; Maximilian J. Steinhardt; Shaji K. Kumar; Angela Dispenzieri; Saurabh Zanwar; Shinichiro Suzuki; Estefania Gauto Mariotti; Dragan Jevremovic; Horatiu Olteanu; Pedro Horna; Gregory Otteson; Francis K. Buadi; David Dingli; Suzanne R. Hayman; Prashant Kapoor; Nelson Leung; Joselle Cook; Nadine Abdallah; Moritz Binder; Rahma Warsame; Taxiarchis V. Kourelis; Ronald S. Go; Yi Lin; Eli Muchtar; S. Vincent Rajkumar; Wilson I. Gonsalves; Morie A. GertzShow moreShow less
Affiliations
1. Division of Hematology, Mayo Clinic, Rochester, USA; 2. Internal Medicine, Mayo Clinic, Rochester, USA; 3. Department of Medical Oncology, Mayo Clinic, Rochester, USA; 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USAShow moreShow less
Source PDF DOI Publisher page
140 days

Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

Authors
Melinda SY Tan; Kye Ling Wong; Cinnie Soekojo; Chandramouli Nagarajan; Sarah Burkhill; Xinhua Li; Ho-Jin Shin; Jong Heon Jung; Yeung-Chul Mun; Ho-Young Yhim; Jae Hoon Lee; Ling Cao; Tadao Ishida; Chihiro Shimazaki; Makoto Sasaki; Hiroyuki Takamatsu; Shinsuke Iida; Hirono Iriuchishima; Shuji Ozaki; Karen Tang; Jeffrey Huang; Jerry Teng; Cheng-Shyong Chang; Changki Min; Wenming Chen; Hiroshi Handa; Kihyun Kim; Priti Bahety; Juan Du; Wee Joo ChngShow moreShow less
Affiliations
1. Department of Hematology, Singapore General Hospital, Singapore, Singapore; 2. Department of Hematology, National Cancer Center Singapore, Singapore, Singapore; 3. National University Cancer Institute of Singapore, Singapore, Singapore; 4. Singapore Clinical Research Institute, Singapore, Singapore; 5. Pusan National University Hospital, Busan, South Korea; 6. National Cancer Center, Goyang, South Korea; 7. Ewha Womens University Mokdong Hospital, Seoul, South Korea; 8. Jeonbuk National University Hospital, Jeonju, South Korea; 9. Gachon University Gil Medical Center, Incheon, South Korea; 10. Tan Tock Seng Hospital, Singapore, Singapore; 11. Japan Red Cross Medical Center, Tokyo, Japan; 12. JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan; 13. Juntendo University Hospital, Bunkyo, Japan; 14. Kanazawa University Hospital, Kanazawa, Japan; 15. Nagoya City University Hospital, Nagoya, Japan; 16. Shibukawa Medical Center, Shibukawa, Japan; 17. Tokushima Prefectural Central Hospital, Tokushima, Japan; 18. Queen Mary Hospital, Hong Kong University, Hong Kong, Hong Kong; 19. National University Taiwan Hospital, Taipei, Taiwan; 20. Taichung Veterens General Hospital, Taichung, Taiwan; 21. Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan; 22. Seoul Saint Mary’s Hospital, Seoul, South Korea; 23. Beijing Chaoyang Hospital, Beijing, China; 24. Gunma University School of Medicine, Maebashi, Japan; 25. Samsung Medical Center Samsung Medical Center, Seoul, South Korea; 26. GlaxoSmithKline Pte Ltd, Singapore, Singapore; 27. Shanghai Chang Zheng Hospital, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
91 days

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Authors
Elizabeth K. O’Donnell; Omar Nadeem; Jacob P. Laubach; Giada Bianchi; Andrew R. Branagan; Brea C. Lipe; Paul G. Richardson; Ehsan Malek; Robb S. Friedman; Ajay K. Nooka; Robert Redd; Noopur S. Raje; Andrew J. YeeShow moreShow less
Affiliations
1. Mass General Brigham Cancer Institute, Boston, USA; 2. Harvard Medical School, Boston, USA; 3. Dana-Farber Cancer Institute, Boston, USA; 4. University of Rochester Medical Center, Rochester, USA; 5. University Hospitals of Cleveland, Cleveland, USA; 6. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 7. Newton-Wellesley Hospital, Newton, USA; 8. Dana-Farber Brigham Cancer Center at South Shore Health, South Weymouth, USA; 9. Winship Cancer Institute, Emory University, Atlanta, USAShow moreShow less
Source PDF DOI Publisher page
74 days

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

Authors
Steffen Koschmieder; Susanne Isfort; Lino L. Teichmann; Philippe Schafhausen; Florian H. Heidel; Carl Crodel; Andreas Hochhaus; Martin Griesshammer; Katja Sockel; Philipp J. Jost; Denise Walther; Konstanze Döhner; Joachim R. Göthert; Markus Radsak; Marinela Augustin; Heiko Becker; Aristoteles Giagounidis; Markus Schaich; Martine Klausmann; Nikolas von Bubnoff; Frank Stegelmann; Maike Kortmann; Michelle Zentis; Julia Frank; Anna Hagemeier; Martin Hellmich; Tim H. BrümmendorfShow moreShow less
Affiliations
1. Department of Medicine (Hematology, Oncology, Hemostaseology, and SCT), Faculty of Medicine, RWTH Aachen University, Aachen, Germany; 2. Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; 3. Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany; 4. Department of Medicine III, University Hospital Bonn, Bonn, Germany; 5. Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6. Clinic for Internal Medicine 2, Jena University Hospital, Jena, Germany; 7. University Clinic for Haematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Centre Minden, University of Bochum, Minden, Germany; 8. Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Germany; 9. Medical Department III, Hematology and Oncology, and Center for Translational Cancer Research, Translatum, Technical University of Munich, Munich, Germany; 10. Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria; 11. Department of Hematology/Oncology and Cell Therapy, Otto-von-Guericke University Magdeburg, Medical Center, Magdeburg, Germany; 12. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; 13. Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany; 14. Department of Hematology and Medical Oncology, UCT Mainz, DKTK, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; 15. Klinikum Nürnberg Nord, Klinik für Innere Medizin 5, Schwerpunkt Onkologie/Hämatologie, Paracelsus Medizinische Privatuniversität, Campus Nürnberg, Nürnberg, Germany; 16. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, German Cancer Consortium (DKTK), partner site Freiburg, University of Freiburg, Freiburg, Germany; 17. Dept. Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany; 18. Department of Hematology, Oncology and Palliative Medicine, Rems-Murr-Klinikum, Winnenden, Germany; 19. Gemeinschaftspraxis, Aschaffenburg, Germany; 20. Department of Hematology and Oncology, University Medical Center Schleswig-Holstein and University Cancer Center Schleswig-Holstein (UCCSH), University of Lübeck, Lübeck, Germany; 21. Center for Translational & Clinical Research (CTC-A), Faculty of Medicine, RWTH Aachen University, Aachen, Germany; 22. Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; 23. Department of Medical Statistics, University Medical Center Göttingen, Göttingen, GermanyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Blood Cancer Journal take to review a manuscript?

As of 2026-11-18, CrushSCI has 27 complete review records for Blood Cancer Journal. The fastest paper went from submission to acceptance in 19 days (Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making, received 2026-06-24, accepted 2026-07-13); the slowest took 203 days. The average is 104.4 days and the median is 91 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.